How to afford a GLP-1 without insurance

If your insurance doesn't cover GLP-1s — or you don't have insurance at all — the list prices look impossible: often four figures a month at the pharmacy counter. The good news is that almost nobody actually pays list price anymore. The cash-pay landscape has changed fast, and there are several legitimate, FDA-approved routes that bring the real monthly cost down substantially. Here's the map.

1. Manufacturer self-pay programs (start here)

Both major manufacturers now sell direct to cash-pay patients — Novo Nordisk through NovoCare and Eli Lilly through LillyDirect. Depending on the drug and dose, self-pay pricing has generally landed in the roughly $150–500/month range — far below list price. As of mid-2026, these programs change their terms and pricing often, so check the current numbers directly. Two things to know: you still need a valid prescription from a licensed clinician, and lower-dose tiers are usually cheaper — your prescriber decides what's right, not the price sheet. (We earn nothing when you buy manufacturer-direct; it's often genuinely the best cash option, which is why we always show it.)

2. Cash-pay telehealth

Branded telehealth programs bundle the online visit, the prescription, and often the medication itself into one monthly price — commonly with a discounted intro month, then an ongoing rate. It's the fastest and most convenient route, and for people without a prescriber it solves two problems at once. The catch: convenience costs something, and the ongoing price after the intro period is what matters. Always compare the 12-month all-in cost, not the first-month teaser.

3. Check whether you qualify for help anyway

• Savings cards mostly require commercial insurance — but if you have any private plan, even one that denied coverage, read our savings-card guide; some tiers help even when insurance won't pay.
• Patient-assistance programs exist for lower-income patients — the manufacturers run them, and they can cut costs dramatically for those who qualify.
• Your employer's plan next enrollment — coverage is expanding year over year; it's worth re-checking every open enrollment.

4. The trap to avoid: mystery-cheap sources

When something is dramatically cheaper than every legitimate option, it's usually compounded — or worse, gray-market. Compounded GLP-1s are not FDA-approved as finished products, aren't evaluated for safety or quality, and regulators are actively restricting them. And anything sold without a prescription at all is an outright red flag. Cheap only counts if it's also safe — a bad batch costs more than any savings.

The bottom line

Paying cash for a GLP-1 in 2026 is genuinely workable: manufacturer self-pay programs and reputable telehealth have pulled real prices down to a fraction of list. The right choice depends on whether you already have a prescriber, how fast you need access, and your monthly budget — which is exactly what our free Access Navigator sorts out in three questions, ranked by what you care about, never by what pays us.